<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xml:lang="EN" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?origin publisher?><?properties no_embargo?><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlm.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Diabetologia</journal-id><journal-title>Diabetologia</journal-title><issn pub-type="ppub">0012-186X</issn><issn pub-type="epub">1432-0428</issn><publisher><publisher-name>Springer-Verlag</publisher-name><publisher-loc>Berlin/Heidelberg</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">19652946</article-id><article-id pub-id-type="publisher-id">1465</article-id><article-id pub-id-type="doi">10.1007/s00125-009-1465-x</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Regulation of skeletal muscle sucrose, non-fermenting 1/AMP-activated protein kinase-related kinase (SNARK) by metabolic stress and diabetes</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Rune</surname><given-names>A.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Osler</surname><given-names>M. E.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Fritz</surname><given-names>T.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Zierath</surname><given-names>J. R.</given-names></name><address><email>Juleen.Zierath@ki.se</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label>Section of Integrative Physiology, Department of Molecular Medicine and Surgery, Karolinska Institutet, von Eulers v&#x000e4;g 4a, 171 77 Stockholm, Sweden </aff><aff id="Aff2"><label>2</label>Center of Family Medicine, Karolinska Institutet, Huddinge, Sweden </aff></contrib-group><pub-date pub-type="epub"><day>4</day><month>8</month><year>2009</year></pub-date><pub-date pub-type="ppub"><month>10</month><year>2009</year></pub-date><volume>52</volume><issue>10</issue><fpage>2182</fpage><lpage>2189</lpage><history><date date-type="received"><day>18</day><month>5</month><year>2009</year></date><date date-type="accepted"><day>18</day><month>6</month><year>2009</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2009</copyright-statement></permissions><abstract xml:lang="EN"><sec><title>Aims/hypothesis</title><p>Sucrose, non-fermenting 1/AMP-activated protein kinase-related kinase (SNARK) is involved in cellular stress responses linked to obesity and type 2 diabetes. We determined the role of SNARK in response to metabolic stress and insulin action on glucose and lipid metabolism in skeletal muscle.</p></sec><sec><title>Methods</title><p>Vastus lateralis skeletal muscle biopsies were obtained from normal glucose tolerant (<italic>n&#x02009;</italic>=&#x02009;35) and type 2 diabetic (<italic>n&#x02009;</italic>=&#x02009;31) men and women for SNARK expression studies. Primary myotube cultures were derived from biopsies obtained from normal glucose tolerant individuals for metabolic studies.</p></sec><sec><title>Results</title><p><italic>SNARK</italic> (also known as <italic>NUAK2</italic>) mRNA expression was unaltered between normal glucose tolerant individuals and type 2 diabetic patients. <italic>SNARK</italic> expression was increased in skeletal muscle from obese (BMI &#x0003e;31&#x000a0;kg/m<sup>2</sup>) normal glucose tolerant individuals and type 2 diabetic patients (1.4- and 1.4-fold, respectively, <italic>p&#x02009;</italic>&#x0003c;&#x02009;0.05) vs overweight (BMI &#x0003c;28&#x000a0;kg/m<sup>2</sup>) normal glucose tolerant individuals and type 2 diabetic patients. <italic>SNARK</italic> mRNA was increased in myotubes exposed to palmitate (12-fold; <italic>p&#x02009;</italic>&#x0003c;&#x02009;0.01), or TNF-&#x003b1; (25-fold, <italic>p&#x02009;</italic>&#x0003c;&#x02009;0.05), but not to oleate, glucose or IL-6, whereas expression of the AMP-activated protein kinase &#x003b1;2 subunit was unaltered. Small interfering (si)RNA against SNARK reduced mRNA and protein in myotubes by 61% and 60%, respectively (<italic>p&#x02009;</italic>&#x0003c;&#x02009;0.05). SNARK siRNA was without effect on basal or insulin-stimulated glucose uptake or lipid oxidation, and insufficient to rescue TNF-&#x003b1;- or palmitate-induced insulin resistance.</p></sec><sec><title>Conclusions/interpretation</title><p>Skeletal muscle <italic>SNARK</italic> expression is increased in human obesity, and in response to metabolic stressors, but not type 2 diabetes. Partial SNARK depletion failed to modify either glucose or lipid metabolism, or protect against TNF-&#x003b1;- or palmitate-induced insulin resistance in primary human myotubes.</p></sec></abstract><kwd-group><title>Keywords</title><kwd>AMPK activation</kwd><kwd>Glucose metabolism</kwd><kwd>Insulin resistance</kwd><kwd>Lipid metabolism</kwd><kwd>Obesity</kwd><kwd>Palmitate</kwd><kwd>Signal transduction</kwd><kwd>siRNA</kwd><kwd>TNF-&#x003b1;</kwd><kwd>Type 2 diabetes</kwd></kwd-group><custom-meta-wrap><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer-Verlag 2009</meta-value></custom-meta></custom-meta-wrap></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p>The ability to adjust energy use and storage in times of fuel surplus or deficiency is vital for survival throughout evolution. AMP-activated protein kinase (AMPK) is known as a master regulator of glucose and lipid metabolism in mammals through sensing of the ratio of AMP:ATP in the cell [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. Upon activation of AMPK, anabolic energy-demanding pathways are switched off and catabolic ATP-producing pathways are activated, thereby controlling peripheral glucose and lipid homeostasis. Recently, a family of AMPK-related kinases has been described, thereby broadening the regulation of metabolism in response to cellular stress to include novel protein kinases [<xref ref-type="bibr" rid="CR3">3</xref>].</p><p>AMPK is a heterotrimeric complex consisting of a catalytic AMP-sensitive &#x003b1; subunit and regulatory &#x003b2; and &#x003b3; subunits. Twelve protein kinases (BRSK1, BRSK2, NUAK1, NUAK2, QIK, QSK, SIK, MARK1, MARK2, MARK3, MARK4 and MELK) closely related to AMPK&#x003b1;<sub>1</sub> and AMPK&#x003b1;<sub>2</sub> have been identified in the human kinome, thus forming a 14 kinase phylogenetic tree known as &#x02018;AMPK-related kinases&#x02019; [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>]. LKB1, an upstream activating kinase of AMPK, phosphorylates and activates 11 of the AMPK-related kinases [<xref ref-type="bibr" rid="CR3">3</xref>]. Although the role of AMPK-related kinases is largely unknown, they do not appear to interact with the regulatory &#x003b2; and &#x003b3; subunits of AMPK [<xref ref-type="bibr" rid="CR5">5</xref>]. Furthermore, the majority of the AMPK-related kinases are not activated by AMP or pharmacological activators of AMPK including 5-aminoimidazole-4-carboxamide-1&#x003b2;-4-ribofuranoside (AICAR) and phenformin [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR6">6</xref>]. Recent evidence suggests that skeletal muscle-selective knockout of LKB1 increases insulin sensitivity [<xref ref-type="bibr" rid="CR7">7</xref>], possibly implicating these novel AMPK-related protein kinases in the regulation of glucose homeostasis.</p><p>Haploinsufficient <italic>Snark</italic> (also known as <italic>Nuak2</italic>) knockout mice develop obesity, hepatic steatosis, altered serum lipid profiles, hyperinsulinaemia, hyperglycaemia and impaired glucose tolerance with age [<xref ref-type="bibr" rid="CR8">8</xref>]. <italic>SNARK</italic> was first identified as an ultraviolet B-induced gene in keratinocytes [<xref ref-type="bibr" rid="CR9">9</xref>]. <italic>SNARK</italic> is located on human chromosome 1q32 and is translated into a single protein of approximately 76&#x000a0;kDa [<xref ref-type="bibr" rid="CR10">10</xref>]. In rats, <italic>Snark</italic> is expressed in multiple tissues, with highest expression in kidney [<xref ref-type="bibr" rid="CR11">11</xref>]. Sucrose, non-fermenting 1/AMP-activated protein kinase-related kinase (SNARK) is activated in a cell-type-specific manner by a variety of stressors including hyperosmotic stress, DNA damage and oxidative stress, as well as nutrients including glucose and glutamine [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR11">11</xref>]. Several aspects of SNARK activation and regulation are broadly similar to AMPK [<xref ref-type="bibr" rid="CR12">12</xref>]. For example, SNARK and AMPK are both AMP-responsive and activated by treatments known to increase the AMP:ATP ratio, including glucose deprivation and chemical ATP production [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR13">13</xref>]. Nevertheless, the metabolic role of SNARK, particularly in humans and at the cellular level in skeletal muscle, is incompletely resolved.</p><p>Given that <italic>Snark</italic>-haploinsufficient mice become obese and glucose-intolerant [<xref ref-type="bibr" rid="CR8">8</xref>], this AMPK-related protein kinase may play a permissive role in energy metabolism. Thus, we tested the hypothesis that SNARK is involved in cellular stress responses associated with obesity and type 2 diabetes. Since skeletal muscle plays an important role in the regulation of whole-body glucose uptake, the aim of this study was to determine the role of SNARK in response to metabolic stress and insulin action on glucose and lipid metabolism in human skeletal muscle.</p></sec><sec id="Sec2" sec-type="methods"><title>Methods</title><p><bold>Study participants and muscle biopsy procedure</bold> Biopsies were obtained using a Weil&#x02013;Blakesley conchotome from vastus lateralis skeletal muscle under local anaesthesia (lidocaine hydrochloride 5&#x000a0;mg/ml) from normal glucose tolerant and type 2 diabetic men and women for mRNA expression analysis of the gene encoding SNARK. Biopsies were snap-frozen and stored in liquid nitrogen until use. The clinical characteristics of the study participants are presented in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>. HOMA2-insulin resistance (IR) values were determined using the HOMA calculator (<ext-link ext-link-type="uri" xlink:href="http://www.dtu.ox.ac.uk">www.dtu.ox.ac.uk</ext-link>). The regional ethical committee at Karolinska Institutet approved all study protocols. Informed written and verbal consent was received from all study participants. <table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>Participant characteristics</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>Sex</th><th>Age (years)</th><th>BMI (kg/m<sup>2</sup>)</th><th>Fasting glucose (mmol/l)</th><th>HbA<sub>1c</sub> (%)</th><th>Triacylglycerol (mmol/l)</th><th>Insulin (pmol/l)</th><th>HOMA2-IR</th></tr></thead><tbody><tr><td colspan="9">Normal glucose tolerant</td></tr><tr><td>&#x000a0;BMI &#x0003c;28&#x000a0;kg/m<sup>2</sup></td><td>10 F/8&#x000a0;M</td><td char="&#x000b1;" align="char">59&#x02009;&#x000b1;&#x02009;1</td><td char="&#x000b1;" align="char">26.2&#x02009;&#x000b1;&#x02009;0.2</td><td char="&#x000b1;" align="char">5.3&#x02009;&#x000b1;&#x02009;0.1</td><td char="&#x000b1;" align="char">4.6&#x02009;&#x000b1;&#x02009;0.05</td><td char="&#x000b1;" align="char">1.15&#x02009;&#x000b1;&#x02009;0.14</td><td char="&#x000b1;" align="char">51.2&#x02009;&#x000b1;&#x02009;9.2</td><td char="&#x000b1;" align="char">1.0&#x02009;&#x000b1;&#x02009;0.2</td></tr><tr><td>&#x000a0;BMI &#x0003e;31&#x000a0;kg/m<sup>2</sup></td><td>11 F/6&#x000a0;M</td><td char="&#x000b1;" align="char">61&#x02009;&#x000b1;&#x02009;1</td><td char="&#x000b1;" align="char">34.4&#x02009;&#x000b1;&#x02009;0.9*</td><td char="&#x000b1;" align="char">5.5&#x02009;&#x000b1;&#x02009;0.1</td><td char="&#x000b1;" align="char">4.8&#x02009;&#x000b1;&#x02009;0.07*</td><td char="&#x000b1;" align="char">1.49&#x02009;&#x000b1;&#x02009;0.14</td><td char="&#x000b1;" align="char">59.7&#x02009;&#x000b1;&#x02009;7.1</td><td char="&#x000b1;" align="char">1.1&#x02009;&#x000b1;&#x02009;0.1</td></tr><tr><td colspan="9">Type 2 diabetic</td></tr><tr><td>&#x000a0;BMI &#x0003c;28&#x000a0;kg/m<sup>2</sup></td><td>2 F/12&#x000a0;M</td><td char="&#x000b1;" align="char">60&#x02009;&#x000b1;&#x02009;1</td><td char="&#x000b1;" align="char">27.0&#x02009;&#x000b1;&#x02009;0.3*</td><td char="&#x000b1;" align="char">7.8&#x02009;&#x000b1;&#x02009;0.4*</td><td char="&#x000b1;" align="char">6.1&#x02009;&#x000b1;&#x02009;0.23*</td><td char="&#x000b1;" align="char">1.34&#x02009;&#x000b1;&#x02009;0.13</td><td char="&#x000b1;" align="char">53.0&#x02009;&#x000b1;&#x02009;6.5</td><td char="&#x000b1;" align="char">1.1&#x02009;&#x000b1;&#x02009;0.1</td></tr><tr><td>&#x000a0;BMI &#x0003e;31&#x000a0;kg/m<sup>2</sup></td><td>3 F/14&#x000a0;M</td><td char="&#x000b1;" align="char">60&#x02009;&#x000b1;&#x02009;1</td><td char="&#x000b1;" align="char">34.5&#x02009;&#x000b1;&#x02009;0.8*</td><td char="&#x000b1;" align="char">7.8&#x02009;&#x000b1;&#x02009;0.4*</td><td char="&#x000b1;" align="char">5.9&#x02009;&#x000b1;&#x02009;0.19*</td><td char="&#x000b1;" align="char">1.53&#x02009;&#x000b1;&#x02009;0.10*</td><td char="&#x000b1;" align="char">91.4&#x02009;&#x000b1;&#x02009;11.5*</td><td char="&#x000b1;" align="char">1.9&#x02009;&#x000b1;&#x02009;0.21*</td></tr></tbody></table><table-wrap-foot><p>Data are means&#x02009;&#x000b1;&#x02009;SE</p><p>*<italic>p&#x02009;</italic>&#x0003c;&#x02009;0.05 compared with normal glucose tolerant individuals with BMI &#x0003c;28&#x000a0;kg/m<sup>2</sup></p><p>F, female; M, male</p></table-wrap-foot></table-wrap></p><p><bold>Skeletal muscle cell cultures and in vitro treatments</bold> Skeletal muscle cell cultures were established from satellite cells isolated from vastus lateralis skeletal muscle biopsies obtained from normal glucose tolerant individuals. Satellite cells were isolated by trypsin&#x02013;EDTA digestion, and myoblasts were cultured and differentiated into myotubes as previously described [<xref ref-type="bibr" rid="CR14">14</xref>]. Myotubes were used to test the effects of a variety of cellular stressors, including nutrients, hormones or cytokines, on <italic>SNARK</italic> mRNA expression. Myotubes were treated with palmitate (0.25&#x000a0;mmol/l), oleate (0.25&#x000a0;mmol/l), glucose (25&#x000a0;mmol/l), TNF-&#x003b1; (20&#x000a0;ng/ml) or IL-6 (20&#x000a0;ng/ml) for 2 or 7&#x000a0;days. <italic>SNARK</italic> mRNA expression was determined as described below.To determine the direct role of <italic>SNARK</italic> on basal and insulin-stimulated glucose and lipid metabolism, myoblasts were transfected with small interfering (si) RNA against a scrambled non-specific sequence or <italic>SNARK</italic> (80&#x000a0;pmol) (Ambion/Applied Biosystems, Foster City, USA) for 16&#x000a0;h before initiation of differentiation and also after 2&#x000a0;days into the differentiation programme using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) in serum- and antibiotic-free DMEM [<xref ref-type="bibr" rid="CR15">15</xref>]. Glucose incorporation into glycogen and lipid oxidation were determined, as described below.</p><p><bold>SNARK mRNA expression</bold><italic>SNARK</italic> mRNA expression was assessed in vastus lateralis skeletal muscle biopsies or primary skeletal muscle cell cultures (myotubes) using quantitative RT-PCR (ABI PRISM 7000 Sequence Detector System; Applied Biosystems). Total RNA was purified from skeletal muscle biopsies using Trizol reagent (Invitrogen, Carlsbad, CA, USA) and from myotubes using an RNeasy Mini Kit (Invitrogen). Purified RNA was treated with DNase I using a DNA-free kit (Ambion) and cDNA synthesis was performed with a SuperScript First Strand Synthesis System (Invitrogen). TaqMan gene expression assays (Hs00388292_m1 and Hs00178903_m1) for <italic>SNARK</italic> and <italic>AMPK&#x003b1;2</italic> (also known as <italic>PRKAA2</italic>) mRNA expression were independently used in multiplex, with &#x003b2;2-microglobulin as a reference gene (Applied Biosystems). All samples where assayed in duplicate. The mRNA relative abundance was calculated using the standard curve method as described by Applied Biosystems.</p><p><bold>Glycogen synthesis in skeletal muscle cells</bold> Glucose incorporation into glycogen was determined as described [<xref ref-type="bibr" rid="CR16">16</xref>]. Myotubes were incubated in the absence or presence of either 6 or 60&#x000a0;nmol/l insulin for 30&#x000a0;min and thereafter incubated for 90&#x000a0;min with <sc>d</sc>-[U-<sup>14</sup>C]glucose (3700&#x000a0;Bq/ml; Amersham, Uppsala, Sweden) in DMEM (1&#x000a0;g glucose/l). When indicated, myotubes were exposed to either palmitate (0.25&#x000a0;mmol/l) or TNF-&#x003b1; (20&#x000a0;ng/ml) for 48&#x000a0;h before the experiment was performed. Experiments were performed in duplicate. Results are reported as nmol glucose (mg protein)<sup>&#x02212;1</sup> h<sup>&#x02212;1</sup>.</p><p><bold>Lipid oxidation in skeletal muscle cells</bold> NEFA oxidation was assessed by exposing myotubes to [<sup>3</sup>H]palmitic acid and measuring the production of <sup>3</sup>H-labelled water. Myotubes were cultured in six well plates and serum starved overnight. Cells were washed once with PBS and incubated for 5.5&#x000a0;h with 1&#x000a0;ml DMEM (1&#x000a0;g glucose/l), supplemented with fatty acid-free BSA (0.2% wt/vol.) and [9,10(<italic>n</italic>)-<sup>3</sup>H]palmitic acid (1850&#x000a0;Bq/ml; Amersham), with or without insulin (120&#x000a0;nmol/l) or AICAR (1&#x000a0;mmol/l; Toronto Research Chemicals, Toronto, ON, Canada). To absorb non-metabolised palmitate, 0.2&#x000a0;ml of the cell supernatant was mixed with 0.8&#x000a0;ml charcoal slurry (0.1&#x000a0;g charcoal powder in 1&#x000a0;ml 0.02&#x000a0;mol/l TRIS&#x02013;HCl buffer, pH 7.5) in a 2&#x000a0;ml Eppendorf tube and shaken for 30&#x000a0;min. Samples were subjected to centrifugation at 18,500&#x000d7;<italic>g</italic> for 15&#x000a0;min, after which 0.3&#x000a0;ml supernatant with <sup>3</sup>H-labelled-bound water was withdrawn, and radioactivity was determined by liquid scintillation counting (WinSpectral 1414 Liquid Scintillation Counter; Wallac, Turku, Finland). Each experiment was performed in duplicate. Results are reported as per cent converted palmitate (mg protein)<sup>&#x02212;1</sup> h<sup>&#x02212;1</sup>.</p><p><bold>Western blot analysis</bold> Lysates were prepared from myotubes transfected with siRNA against a scrambled sequence or SNARK. Proteins were separated by SDS-PAGE and subjected to immunoblot analysis with an antibody directed against SNARK (Proteintech, Manchester, UK). Proteins where visualised by enhanced chemiluminescence and quantified by densiometry. Results are reported as arbitrary units and normalised to a loading control (desmin).</p><p><bold>Statistics</bold> Results are presented as means&#x02009;&#x000b1;&#x02009;SE. Differences between groups were determined by Student&#x02019;s <italic>t</italic> test or two-way ANOVA. When ANOVA was applied, pair-wise multiple comparison procedures were performed using the Holm&#x02013;Sidak method at a significance level of 0.05.</p></sec><sec id="Sec3" sec-type="results"><title>Results</title><p><bold>Skeletal muscle SNARK mRNA expression is increased with obesity but not in diabetes</bold><italic>SNARK</italic> mRNA expression was determined in vastus lateralis skeletal muscle biopsies from normal glucose tolerant and type 2 diabetic men and women (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). Type 2 diabetic patients had fasting hyperglycaemia, and elevated HbA<sub>1c</sub> levels, compared with normal glucose tolerant individuals (<italic>p&#x02009;</italic>&#x0003c;&#x02009;0.05). Individuals were stratified into two groups based on BMI. The metabolic derangements were exacerbated in the obese (BMI &#x0003e;31&#x000a0;kg/m<sup>2</sup>) vs overweight (BMI &#x0003c;28&#x000a0;kg/m<sup>2</sup>) type 2 diabetic patients, who also had increased HOMA2-IR values (<italic>p&#x02009;</italic>&#x0003c;&#x02009;0.05). <italic>SNARK</italic> mRNA expression was increased 1.4-fold in obese normal glucose tolerant individuals (BMI &#x0003e;31&#x000a0;kg/m<sup>2</sup>) vs overweight normal glucose tolerant individuals (BMI &#x0003c;28&#x000a0;kg/m<sup>2</sup>). <italic>SNARK</italic> mRNA was also increased 1.4-fold in obese type 2 diabetic patients (BMI &#x0003e;31&#x000a0;kg/m<sup>2</sup>) vs overweight type 2 diabetic patients (BMI &#x0003c;28&#x000a0;kg/m<sup>2</sup>). <italic>SNARK</italic> mRNA expression was similar in normal glucose tolerant and type 2 diabetic patients, irrespectively of BMI. <fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p><italic>SNARK</italic> mRNA expression was determined in vastus lateralis skeletal muscle biopsies from normal glucose tolerant individuals and type 2 diabetic patients with BMI &#x0003c;28&#x000a0;kg/m<sup>2</sup> (white bars) and BMI &#x0003e;31&#x000a0;kg/m<sup>2</sup> (black bars). Result are reported in arbitrary units (A.U.) as means&#x02009;&#x000b1;&#x02009;SE for <italic>n&#x02009;</italic>=&#x02009;14&#x02013;18 individuals. *<italic>p&#x02009;</italic>&#x0003c;&#x02009;0.05 compared with normal glucose tolerant individuals with BMI &#x0003c;28&#x000a0;kg/m<sup>2</sup></p></caption><graphic position="anchor" xlink:href="125_2009_1465_Fig1_HTML" id="MO1"/></fig></p><p><bold>Effects of cellular stressors on SNARK mRNA expression</bold><italic>SNARK</italic> mRNA expression was assessed in cultured myotubes treated with a variety of nutrients or cytokines for 2&#x000a0;days (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2a</xref>). Exposure of myotubes to either palmitate (12-fold; <italic>p&#x02009;</italic>&#x0003c;&#x02009;0.01) or TNF-&#x003b1; (25-fold, <italic>p&#x02009;</italic>&#x0003c;&#x02009;0.05), but not oleate, glucose or IL-6, increased <italic>SNARK</italic> mRNA expression compared with untreated myotubes, whereas expression of the <italic>AMPK&#x003b1;2</italic> subunit was unaltered (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2b</xref>). Similar responses on <italic>SNARK</italic> mRNA expression were also observed in myotubes exposed to these metabolic stressors for 7&#x000a0;days (data not shown). Furthermore, <italic>SNARK</italic> mRNA expression was unaltered following exposure of myotubes to AMPK activators, including AICAR, metformin or rosiglitazone (data not shown). <fig id="Fig2"><label>Fig.&#x000a0;2</label><caption><p>Effect of cellular stressors on <italic>SNARK</italic> mRNA expression. Cultured myoblasts were treated with palmitate (0.25&#x000a0;mmol/l), oleate (0.25&#x000a0;mmol/l), glucose (25&#x000a0;mmol/l), TNF-&#x003b1; (20&#x000a0;ng/ml) or IL-6 (20&#x000a0;ng/ml) for 2&#x000a0;days followed by assessment of <italic>SNARK</italic> mRNA expression (<bold>a</bold>) and <italic>AMPK&#x003b1;2</italic> mRNA expression (<bold>b</bold>). Results are reported in arbitrary units (A.U.) as means&#x02009;&#x000b1;&#x02009;SE for <italic>n&#x02009;</italic>=&#x02009;5 individual cultures. *<italic>p&#x02009;</italic>&#x0003c;&#x02009;0.05 compared with unstimulated control cells</p></caption><graphic position="anchor" xlink:href="125_2009_1465_Fig2_HTML" id="MO2"/></fig></p><p><bold>SNARK silencing in myotubes</bold> The effect of <italic>SNARK</italic> gene silencing on mRNA expression (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3a</xref>) and protein level (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3b</xref>) was determined in cultured myotubes. siRNA against SNARK reduced mRNA expression by&#x000a0;61% and protein content by 60% compared with myotubes transfected with siRNA against a scrambled sequence. <fig id="Fig3"><label>Fig.&#x000a0;3</label><caption><p><italic>SNARK</italic> gene silencing in primary human myotubes. The effect of <italic>SNARK</italic> siRNA was determined on mRNA expression (<bold>a</bold>) and protein levels (<bold>b</bold>). Results are reported in arbitrary units (A.U.) as means&#x02009;&#x000b1;&#x02009;SE for <italic>n&#x02009;</italic>=&#x02009;4 individual cultures. *<italic>p&#x02009;</italic>&#x0003c;&#x02009;0.05 compared with myotubes treated with siRNA against a scrambled (Scr) sequence. IB, immunoblot</p></caption><graphic position="anchor" xlink:href="125_2009_1465_Fig3_HTML" id="MO3"/></fig></p><p><bold>Role of SNARK on glucose incorporation into glycogen</bold> Glucose incorporation into glycogen was assessed in myotubes transfected with siRNA against a scrambled sequence or <italic>SNARK</italic> (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>). Insulin increased glucose incorporation into glycogen in myotubes transfected with siRNA against a scrambled sequence (1.8- and 2.3-fold in the presence of 6 or 60&#x000a0;nmol/l insulin, respectively; <italic>p&#x02009;</italic>&#x0003c;&#x02009;0.05 vs basal). Similar effects of insulin on glucose incorporation into glycogen were noted for myotubes transfected with siRNA against <italic>SNARK</italic> (1.8- and 2.4-fold increase in the presence of 6 or 60&#x000a0;nmol/l insulin, respectively; <italic>p&#x02009;</italic>&#x0003c;&#x02009;0.05 vs basal). <italic>SNARK</italic> silencing did not influence basal and insulin-stimulated glucose incorporation into glycogen. <fig id="Fig4"><label>Fig.&#x000a0;4</label><caption><p>Role of <italic>SNARK</italic> in glucose incorporation into glycogen. Glucose incorporation into glycogen was measured in myotubes transfected with either siRNA against a scrambled sequence (Scr) or <italic>SNARK</italic> and incubated in the absence (basal; white bars) or presence of a submaximal (6&#x000a0;nmol/l; grey bars) or maximal (60&#x000a0;nmol/l; black bars) concentration of insulin. Results are means&#x02009;&#x000b1;&#x02009;SE for <italic>n&#x02009;</italic>=&#x02009;8 individuals cultures. *<italic>p&#x02009;</italic>&#x0003c;&#x02009;0.05 compared with basal scrambled siRNA-transfected myotubes</p></caption><graphic position="anchor" xlink:href="125_2009_1465_Fig4_HTML" id="MO4"/></fig></p><p><bold>Role of SNARK on lipid oxidation</bold> Lipid oxidation was determined in myotubes transfected with siRNA against a scrambled sequence or <italic>SNARK</italic> (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>). Insulin suppressed lipid oxidation in myotubes transfected with siRNA against a scrambled sequence (14%; <italic>p&#x02009;</italic>&#x0003c;&#x02009;0.05) and this effect was unaltered by <italic>SNARK</italic> silencing. AICAR increased lipid oxidation in myotubes transfected with siRNA against either a scrambled sequence (3.5-fold; <italic>p&#x02009;</italic>&#x0003c;&#x02009;0.01) or <italic>SNARK</italic> (3.2-fold; <italic>p&#x02009;</italic>&#x0003c;&#x02009;0.01) vs the basal condition. Thus, <italic>SNARK</italic> silencing did not influence basal or insulin- or AICAR-stimulated lipid oxidation. <fig id="Fig5"><label>Fig.&#x000a0;5</label><caption><p>Role of <italic>SNARK</italic> in lipid oxidation. Lipid oxidation was measured in myotubes transfected with siRNA against either a scrambled sequence (Scr) or <italic>SNARK</italic> and incubated in the absence (basal; white bars) or presence of either insulin (60&#x000a0;nmol/l; grey bars) or AICAR (1&#x000a0;mmol/l; black bars). Results are means&#x02009;&#x000b1;&#x02009;SE for <italic>n&#x02009;</italic>=&#x02009;8 individuals cultures. *<italic>p&#x02009;</italic>&#x0003c;&#x02009;0.05 compared with basal scrambled siRNA-transfected myotubes</p></caption><graphic position="anchor" xlink:href="125_2009_1465_Fig5_HTML" id="MO5"/></fig></p><p><bold>Effect of SNARK silencing on TNF-&#x003b1;- or palmitate-induced insulin resistance</bold> Given that TNF-&#x003b1; and palmitate treatment markedly increased <italic>SNARK</italic> mRNA expression, we also examined whether protein levels were altered under these conditions (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6a</xref>). Exposure of myotubes to either TNF-&#x003b1; or palmitate for 48&#x000a0;h increased SNARK protein content (<italic>p&#x02009;</italic>&#x0003c;&#x02009;0.05). <italic>SNARK</italic> silencing reduced protein content by 56% (<italic>p&#x02009;</italic>&#x0003c;&#x02009;0.05), and completely prevented the effect of either TNF-&#x003b1; or palmitate to increase SNARK protein. <fig id="Fig6"><label>Fig.&#x000a0;6</label><caption><p>Effect of <italic>SNARK</italic> silencing on TNF-&#x003b1;- and palmitate-induced insulin resistance. Human myotubes were transfected with either siRNA against a scrambled sequence (Scr) or <italic>SNARK</italic> and incubated in the absence (basal; white bars) or presence of TNF-&#x003b1; (20&#x000a0;ng/ml; grey bars) or palmitate (0.25&#x000a0;nmol/l; black bars) for 48&#x000a0;h. The effect of <italic>SNARK</italic> siRNA silencing was determined on protein levels (<bold>a</bold>), and glucose incorporation into glycogen was measured in the absence or presence of insulin (<bold>b</bold>). Results are means&#x02009;&#x000b1;&#x02009;SE for <italic>n&#x02009;</italic>=&#x02009;4 individuals. *<italic>p&#x02009;</italic>&#x0003c;&#x02009;0.05 compared with myotubes incubated in the absence of insulin. &#x02020;<italic>p&#x02009;</italic>&#x0003c;&#x02009;0.05 compared with myotubes incubated in the absence of TNF-&#x003b1; and palmitate (basal). A.U. arbitrary units; IB, immunoblot</p></caption><graphic position="anchor" xlink:href="125_2009_1465_Fig6_HTML" id="MO6"/></fig>Exposure of myotubes to TNF-&#x003b1; or palmitate induces insulin resistance in cultured human myotubes [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR18">18</xref>], coincident with increased <italic>SNARK</italic> expression (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2a</xref>). Thus, we determined whether <italic>SNARK</italic> silencing prevents insulin resistance arising from these factors (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6b</xref>). Myotubes were transfected with siRNA against either a scrambled sequence or <italic>SNARK</italic> and incubated for 48&#x000a0;h in the absence or presence of TNF-&#x003b1; (20&#x000a0;ng/ml) or palmitate (0.25&#x000a0;mmol/l). TNF-&#x003b1; exposure decreased insulin-stimulated glucose incorporation into glycogen by 41% in the presence of 6&#x000a0;nmol/l (<italic>p&#x02009;</italic>&#x0003c;&#x02009;0.05), but not 60&#x000a0;nmol/l insulin, in myotubes treated with siRNA against either a scrambled sequence or <italic>SNARK</italic>. Thus, siRNA against <italic>SNARK</italic> does not protect against TNF-&#x003b1;-induced insulin resistance. Palmitate exposure decreased insulin-stimulated glucose incorporation into glycogen by 37% in the presence of 60&#x000a0;nmol/l insulin (<italic>p&#x02009;</italic>&#x0003c;&#x02009;0.01), but not 6&#x000a0;nmol/l insulin, in myotubes treated with siRNA against either a scrambled sequence or SNARK. Thus, siRNA against <italic>SNARK</italic> does not protect against palmitate-induced insulin resistance.</p></sec><sec id="Sec4" sec-type="discussion"><title>Discussion</title><p>The AMPK-related kinase SNARK plays a role in whole-body glucose and energy homeostasis [<xref ref-type="bibr" rid="CR8">8</xref>]. Whole-body <italic>Snark</italic>-haploinsufficient mice are obese and glucose-intolerant, implicating an important role for this AMPK-related protein kinase in the regulation of energy and glucose homeostasis [<xref ref-type="bibr" rid="CR8">8</xref>]. Here we tested the hypothesis that SNARK is involved in cellular stress responses linked to the development of insulin resistance in obesity and type 2 diabetes. We provide evidence that <italic>SNARK</italic> mRNA expression is increased in skeletal muscle from obese normal glucose tolerant and type 2 diabetic men and women. The increase in <italic>SNARK</italic> mRNA was unaltered between normal glucose tolerant and type 2 diabetic individuals irrespectively of BMI, indicating the influence of obesity, rather than diabetes per se. Based on the phenotype of the <italic>Snark</italic>-haploinsufficient mice [<xref ref-type="bibr" rid="CR8">8</xref>], an increase in <italic>SNARK</italic> mRNA expression would be predicted to have a positive effect on energy and glucose homeostasis, but this does not appear to be the case, at least in humans. We also report that elevated levels of TNF-&#x003b1; or palmitate, systemic factors implicated in obesity-induced insulin resistance, increased <italic>SNARK</italic> expression in cultured human skeletal muscle myotubes. Nevertheless, a 60% reduction in <italic>SNARK</italic> mRNA by siRNA-mediated gene silencing (an effect similar to that achieved in whole-body <italic>Snark</italic>-haploinsufficient mice [<xref ref-type="bibr" rid="CR8">8</xref>]), was without effect on basal or insulin-stimulated glucose uptake and lipid oxidation. Furthermore, <italic>SNARK</italic> silencing did not prevent TNF-&#x003b1;- or palmitate-induced insulin resistance in skeletal muscle. Thus, while obesity and associated systemic factors, such as TNF-&#x003b1; or palmitate increase <italic>SNARK</italic> mRNA expression, insulin resistance induced by these factors occurs via a SNARK-independent mechanism.</p><p><italic>Snark</italic>-haploinsufficient mice, with a 50% reduction of whole-body <italic>Snark</italic> mRNA expression, develop obesity and insulin resistance, as evidenced by increased adiposity, fatty liver, increased serum triacylglycerol, hyperinsulinaemia, hyperglycaemia and glucose intolerance [<xref ref-type="bibr" rid="CR8">8</xref>]. Thus, our findings of increased skeletal muscle <italic>SNARK</italic> mRNA expression in obese humans and in response to elevated levels of TNF-&#x003b1; or palmitate in vitro, suggest that the metabolic phenotype observed in total-body <italic>Snark</italic>-haploinsufficient mice is unlikely to arise from a direct effect of SNARK in skeletal muscle. Rather, these results implicate a role for SNARK in other tissues, particularly since skeletal muscle expresses relatively low levels of SNARK compared with liver, kidney, intestine and testis in rodents [<xref ref-type="bibr" rid="CR11">11</xref>]. The development of mature-onset obesity in whole-body <italic>Snark-</italic>heterozygous mice might occur from a central defect that modifies food intake and activity levels, rather than a direct effect in peripheral tissues. The absence of a basal energetic defect in skeletal muscle of <italic>Snark</italic>-heterozygous mice, as well as an unexplained increased motivation/drive for voluntary exercise supports this contention [<xref ref-type="bibr" rid="CR19">19</xref>]. Fibre type composition and number is unaffected in <italic>Snark-</italic>heterozygous mice, indicating <italic>Snark</italic> expression and activity in tissues other than skeletal muscle may contribute to the regulation of glucose and energy homeostasis and motivation for physical activity. For example, impairments in brown adipose tissue may contribute to the obesity phenotype, since whole-body temperature and energy expenditure was reduced in these mice. Further studies using tissue-specific <italic>Snark</italic> knockout mice may resolve this paradox.</p><p>The identification of an AMPK subfamily [<xref ref-type="bibr" rid="CR3">3</xref>] raises questions about the involvement of these protein kinases in whole-body and cellular glucose and energy homeostasis, as well as the possibility that they might regulate cellular and whole-body metabolic and gene regulatory responses in a manner analogous to AMPK. <italic>Lkb1</italic> (also known as <italic>Stk11</italic>) knockout mice have been important in the evaluation of the metabolic role of the AMPK-related kinases, since it is a master kinase that activates the majority of the members of this subfamily [<xref ref-type="bibr" rid="CR3">3</xref>]. For example, contraction-mediated glucose uptake is inhibited in skeletal muscle from <italic>Lkb1</italic> knockout mice [<xref ref-type="bibr" rid="CR20">20</xref>] and kinase-dead <italic>Ampk&#x003b1;2</italic> transgenic mice [<xref ref-type="bibr" rid="CR21">21</xref>], but not <italic>Ampk&#x003b1;1</italic> and <italic>Ampk&#x003b1;2</italic> isoform-specific knockout mice [<xref ref-type="bibr" rid="CR22">22</xref>], indicating both AMPK-dependent and AMPK-independent pathways may play a role. Moreover, skeletal muscle-selective knockout of <italic>Lkb1</italic> increases whole-body and skeletal muscle insulin sensitivity and improves glucose homeostasis [<xref ref-type="bibr" rid="CR7">7</xref>], implicating AMPK-related protein kinases participate in the negative regulation of insulin action. Given our observation that <italic>SNARK</italic> mRNA expression was elevated in skeletal muscle from obese humans and myotubes exposed to TNF-&#x003b1; or palmitate, we tested the hypothesis that <italic>SNARK</italic> silencing would directly alter insulin action on glucose and lipid metabolism. However, neither basal nor insulin-stimulated glucose incorporation into glycogen was altered by <italic>SNARK</italic> silencing in primary human myotubes. Furthermore, basal, as well as insulin- or AICAR-stimulated beta oxidation was unchanged by <italic>SNARK</italic> silencing. This contrasts with earlier findings which revealed that <italic>AMPK&#x003b1;</italic> subunit silencing prevents the effects of IL-6 to promote beta oxidation into human myotubes [<xref ref-type="bibr" rid="CR23">23</xref>]. Thus, AMPK, rather than SNARK, appears to control lipid oxidation in skeletal muscle. Although siRNA against <italic>SNARK</italic> reduced mRNA expression by&#x000a0;60%, we cannot exclude the possibility that a total knockout of <italic>SNARK</italic> may be required to reveal effects on glucose and lipid metabolism.</p><p>Our observation of increased <italic>SNARK</italic> mRNA expression in skeletal muscle from obese humans, and in response to TNF-&#x003b1; or palmitate treatment, potentially connects <italic>SNARK</italic> to metabolic regulation in response to cellular stress signals. For example, TNF-&#x003b1; secretion from adipose tissue is increased and IL-6 serum levels are elevated in obese insulin-resistant individuals [<xref ref-type="bibr" rid="CR24">24</xref>]. Thus, the intracellular communication between adipocytes or macrophages in obesity may provide stress signals that increase <italic>SNARK</italic> expression in skeletal muscle, which may modify insulin action. Nevertheless, siRNA against <italic>SNARK</italic> failed to prevent the development of TNF-&#x003b1;- or palmitate-induced insulin resistance on glucose incorporation into glycogen. Previous studies from our laboratory provide evidence that siRNA-mediated reduction of either the mitogen-activated protein kinase kinase kinase kinase isoform 4 [<xref ref-type="bibr" rid="CR15">15</xref>] or the inhibitor of nuclear factor-kappa&#x003b2; (NF-&#x003ba;&#x003b2;) kinase [<xref ref-type="bibr" rid="CR17">17</xref>] prevents TNF-&#x003b1;-induced insulin resistance in human skeletal muscle. Interestingly, SNARK has anti-apoptotic properties, acting through a TNF-&#x003b1;-sensitive nuclear NF-&#x003ba;&#x003b2;-mediated mechanism [<xref ref-type="bibr" rid="CR25">25</xref>]. Thus, the increase in <italic>SNARK</italic> expression may be a consequence, rather than a cause of skeletal muscle insulin resistance.</p><p>In conclusion, we provide evidence against a role for SNARK in the regulation of skeletal muscle glucose or lipid metabolism. Nevertheless, obesity, but not type 2 diabetes, is associated with an increase in skeletal muscle <italic>SNARK</italic> mRNA expression in humans. This increase in <italic>SNARK</italic> mRNA expression may occur as a consequence of systemic factors associated with metabolic impairments in obesity, since exposure of myotubes to elevated levels of TNF-&#x003b1; or palmitate acutely increased <italic>SNARK</italic> mRNA expression. siRNA against <italic>SNARK</italic> failed to rescue TNF-&#x003b1;- or palmitate-induced insulin resistance, indicating changes in <italic>SNARK</italic> expression occur as a consequence, rather than a cause of insulin resistance. Based on our findings in human skeletal muscle, and the insulin-resistant and obesity phenotype in whole-body <italic>Snark-</italic>haploinsufficient mice [<xref ref-type="bibr" rid="CR8">8</xref>], <italic>SNARK</italic> expression in metabolically active tissues beyond skeletal muscle may play a role in whole-body energy and glucose homeostasis.</p></sec></body><back><ack><title>Acknowledgements</title><p>This study was supported by grants from the European Research Council, the European Foundation for the Study of Diabetes, the Swedish Research Council, the Swedish Diabetes Association, the Strategic Research Foundation, the Knut and Alice Wallenberg Foundation, the Novo Nordisk Research Foundation and the Commission of the European Communities (Contract No LSHM-CT-2004-005272 EXGENESIS and Contract No LSHM-CT-2004-512013 EUGENE2).</p><p><bold>Duality of interest</bold> The authors declare that there is no duality of interest associated with this manuscript.</p><p><bold>Open Access</bold> This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.</p></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Long</surname><given-names>YC</given-names></name><name><surname>Zierath</surname><given-names>JR</given-names></name></person-group><article-title>Influence of AMP-activated protein kinase and calcineurin on metabolic networks in skeletal muscle</article-title><source>Am J Physiol Endocrinol Metab</source><year>2008</year><volume>295</volume><fpage>E545</fpage><lpage>E552</lpage><pub-id pub-id-type="doi">10.1152/ajpendo.90259.2008</pub-id></citation><citation citation-type="display-unstructured">Long YC, Zierath JR (2008) Influence of AMP-activated protein kinase and calcineurin on metabolic networks in skeletal muscle. Am J Physiol Endocrinol Metab 295:E545&#x02013;E552 <pub-id pub-id-type="pmid">18544643</pub-id></citation></ref><ref id="CR2"><label>2.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hardie</surname><given-names>DG</given-names></name></person-group><article-title>AMPK: a key regulator of energy balance in the single cell and the whole organism</article-title><source>Int J Obes (Lond)</source><year>2008</year><volume>32</volume><issue>Suppl 4</issue><fpage>S7</fpage><lpage>S12</lpage><pub-id pub-id-type="doi">10.1038/ijo.2008.116</pub-id></citation><citation citation-type="display-unstructured">Hardie DG (2008) AMPK: a key regulator of energy balance in the single cell and the whole organism. Int J Obes (Lond) 32(Suppl 4):S7&#x02013;S12 <pub-id pub-id-type="pmid">18719601</pub-id></citation></ref><ref id="CR3"><label>3.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lizcano</surname><given-names>JM</given-names></name><name><surname>Goransson</surname><given-names>O</given-names></name><name><surname>Toth</surname><given-names>R</given-names></name><etal/></person-group><article-title>LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, including MARK/PAR-1</article-title><source>EMBO J</source><year>2004</year><volume>23</volume><fpage>833</fpage><lpage>843</lpage><pub-id pub-id-type="doi">10.1038/sj.emboj.7600110</pub-id></citation><citation citation-type="display-unstructured">Lizcano JM, Goransson O, Toth R et al (2004) LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, including MARK/PAR-1. EMBO J 23:833&#x02013;843 <pub-id pub-id-type="pmid">14976552</pub-id></citation></ref><ref id="CR4"><label>4.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Manning</surname><given-names>G</given-names></name><name><surname>Whyte</surname><given-names>DB</given-names></name><name><surname>Martinez</surname><given-names>R</given-names></name><name><surname>Hunter</surname><given-names>T</given-names></name><name><surname>Sudarsanam</surname><given-names>S</given-names></name></person-group><article-title>The protein kinase complement of the human genome</article-title><source>Science</source><year>2002</year><volume>298</volume><fpage>1912</fpage><lpage>1934</lpage><pub-id pub-id-type="doi">10.1126/science.1075762</pub-id></citation><citation citation-type="display-unstructured">Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S (2002) The protein kinase complement of the human genome. Science 298:1912&#x02013;1934 <pub-id pub-id-type="pmid">12471243</pub-id></citation></ref><ref id="CR5"><label>5.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Al-Hakim</surname><given-names>AK</given-names></name><name><surname>Goransson</surname><given-names>O</given-names></name><name><surname>Deak</surname><given-names>M</given-names></name><etal/></person-group><article-title>14-3-3 cooperates with LKB1 to regulate the activity and localization of QSK and SIK</article-title><source>J Cell Sci</source><year>2005</year><volume>118</volume><fpage>5661</fpage><lpage>5673</lpage><pub-id pub-id-type="doi">10.1242/jcs.02670</pub-id></citation><citation citation-type="display-unstructured">Al-Hakim AK, Goransson O, Deak M et al (2005) 14-3-3 cooperates with LKB1 to regulate the activity and localization of QSK and SIK. J Cell Sci 118:5661&#x02013;5673 <pub-id pub-id-type="pmid">16306228</pub-id></citation></ref><ref id="CR6"><label>6.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sakamoto</surname><given-names>K</given-names></name><name><surname>Goransson</surname><given-names>O</given-names></name><name><surname>Hardie</surname><given-names>DG</given-names></name><name><surname>Alessi</surname><given-names>DR</given-names></name></person-group><article-title>Activity of LKB1 and AMPK-related kinases in skeletal muscle: effects of contraction, phenformin, and AICAR</article-title><source>Am J Physiol Endocrinol Metab</source><year>2004</year><volume>287</volume><fpage>E310</fpage><lpage>E317</lpage><pub-id pub-id-type="doi">10.1152/ajpendo.00074.2004</pub-id></citation><citation citation-type="display-unstructured">Sakamoto K, Goransson O, Hardie DG, Alessi DR (2004) Activity of LKB1 and AMPK-related kinases in skeletal muscle: effects of contraction, phenformin, and AICAR. Am J Physiol Endocrinol Metab 287:E310&#x02013;E317 <pub-id pub-id-type="pmid">15068958</pub-id></citation></ref><ref id="CR7"><label>7.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Koh</surname><given-names>HJ</given-names></name><name><surname>Arnolds</surname><given-names>DE</given-names></name><name><surname>Fujii</surname><given-names>N</given-names></name><etal/></person-group><article-title>Skeletal muscle-selective knockout of LKB1 increases insulin sensitivity, improves glucose homeostasis, and decreases TRB3</article-title><source>Mol Cell Biol</source><year>2006</year><volume>26</volume><fpage>8217</fpage><lpage>8227</lpage><pub-id pub-id-type="doi">10.1128/MCB.00979-06</pub-id></citation><citation citation-type="display-unstructured">Koh HJ, Arnolds DE, Fujii N et al (2006) Skeletal muscle-selective knockout of LKB1 increases insulin sensitivity, improves glucose homeostasis, and decreases TRB3. Mol Cell Biol 26:8217&#x02013;8227 <pub-id pub-id-type="pmid">16966378</pub-id></citation></ref><ref id="CR8"><label>8.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tsuchihara</surname><given-names>K</given-names></name><name><surname>Ogura</surname><given-names>T</given-names></name><name><surname>Fujioka</surname><given-names>R</given-names></name><etal/></person-group><article-title>Susceptibility of Snark-deficient mice to azoxymethane-induced colorectal tumorigenesis and the formation of aberrant crypt foci</article-title><source>Cancer Sci</source><year>2008</year><volume>99</volume><fpage>677</fpage><lpage>682</lpage><pub-id pub-id-type="doi">10.1111/j.1349-7006.2008.00734.x</pub-id></citation><citation citation-type="display-unstructured">Tsuchihara K, Ogura T, Fujioka R et al (2008) Susceptibility of Snark-deficient mice to azoxymethane-induced colorectal tumorigenesis and the formation of aberrant crypt foci. Cancer Sci 99:677&#x02013;682 <pub-id pub-id-type="pmid">18307533</pub-id></citation></ref><ref id="CR9"><label>9.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rosen</surname><given-names>CF</given-names></name><name><surname>Poon</surname><given-names>R</given-names></name><name><surname>Drucker</surname><given-names>DJ</given-names></name></person-group><article-title>UVB radiation-activated genes induced by transcriptional and posttranscriptional mechanisms in rat keratinocytes</article-title><source>Am J Physiol</source><year>1995</year><volume>268</volume><fpage>C846</fpage><lpage>C855</lpage></citation><citation citation-type="display-unstructured">Rosen CF, Poon R, Drucker DJ (1995) UVB radiation-activated genes induced by transcriptional and posttranscriptional mechanisms in rat keratinocytes. Am J Physiol 268:C846&#x02013;C855 <pub-id pub-id-type="pmid">7733233</pub-id></citation></ref><ref id="CR10"><label>10.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lefebvre</surname><given-names>DL</given-names></name><name><surname>Bai</surname><given-names>Y</given-names></name><name><surname>Shahmolky</surname><given-names>N</given-names></name><etal/></person-group><article-title>Identification and characterization of a novel sucrose-non-fermenting protein kinase/AMP-activated protein kinase-related protein kinase, SNARK</article-title><source>Biochem J</source><year>2001</year><volume>355</volume><fpage>297</fpage><lpage>305</lpage><pub-id pub-id-type="doi">10.1042/0264-6021:3550297</pub-id></citation><citation citation-type="display-unstructured">Lefebvre DL, Bai Y, Shahmolky N et al (2001) Identification and characterization of a novel sucrose-non-fermenting protein kinase/AMP-activated protein kinase-related protein kinase, SNARK. Biochem J 355:297&#x02013;305 <pub-id pub-id-type="pmid">11284715</pub-id></citation></ref><ref id="CR11"><label>11.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lefebvre</surname><given-names>DL</given-names></name><name><surname>Rosen</surname><given-names>CF</given-names></name></person-group><article-title>Regulation of SNARK activity in response to cellular stresses</article-title><source>Biochim Biophys Acta</source><year>2005</year><volume>1724</volume><fpage>71</fpage><lpage>85</lpage></citation><citation citation-type="display-unstructured">Lefebvre DL, Rosen CF (2005) Regulation of SNARK activity in response to cellular stresses. Biochim Biophys Acta 1724:71&#x02013;85 <pub-id pub-id-type="pmid">15893879</pub-id></citation></ref><ref id="CR12"><label>12.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Egan</surname><given-names>B</given-names></name><name><surname>Zierath</surname><given-names>JR</given-names></name></person-group><article-title>Hunting for the SNARK in metabolic disease</article-title><source>Am J Physiol Endocrinol Metab</source><year>2009</year><volume>296</volume><fpage>E969</fpage><lpage>E972</lpage><pub-id pub-id-type="doi">10.1152/ajpendo.00178.2009</pub-id></citation><citation citation-type="display-unstructured">Egan B, Zierath JR (2009) Hunting for the SNARK in metabolic disease. Am J Physiol Endocrinol Metab 296:E969&#x02013;E972 <pub-id pub-id-type="pmid">19318516</pub-id></citation></ref><ref id="CR13"><label>13.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kuga</surname><given-names>W</given-names></name><name><surname>Tsuchihara</surname><given-names>K</given-names></name><name><surname>Ogura</surname><given-names>T</given-names></name><etal/></person-group><article-title>Nuclear localization of SNARK; its impact on gene expression</article-title><source>Biochem Biophys Res Commun</source><year>2008</year><volume>377</volume><fpage>1062</fpage><lpage>1066</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2008.10.143</pub-id></citation><citation citation-type="display-unstructured">Kuga W, Tsuchihara K, Ogura T et al (2008) Nuclear localization of SNARK; its impact on gene expression. Biochem Biophys Res Commun 377:1062&#x02013;1066 <pub-id pub-id-type="pmid">18992219</pub-id></citation></ref><ref id="CR14"><label>14.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Al-Khalili</surname><given-names>L</given-names></name><name><surname>Kramer</surname><given-names>D</given-names></name><name><surname>Wretenberg</surname><given-names>P</given-names></name><name><surname>Krook</surname><given-names>A</given-names></name></person-group><article-title>Human skeletal muscle cell differentiation is associated with changes in myogenic markers and enhanced insulin-mediated MAPK and PKB phosphorylation</article-title><source>Acta Physiol Scand</source><year>2004</year><volume>180</volume><fpage>395</fpage><lpage>403</lpage><pub-id pub-id-type="doi">10.1111/j.1365-201X.2004.01259.x</pub-id></citation><citation citation-type="display-unstructured">Al-Khalili L, Kramer D, Wretenberg P, Krook A (2004) Human skeletal muscle cell differentiation is associated with changes in myogenic markers and enhanced insulin-mediated MAPK and PKB phosphorylation. Acta Physiol Scand 180:395&#x02013;403 <pub-id pub-id-type="pmid">15030381</pub-id></citation></ref><ref id="CR15"><label>15.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bouzakri</surname><given-names>K</given-names></name><name><surname>Zierath</surname><given-names>JR</given-names></name></person-group><article-title>MAP4K4 gene silencing in human skeletal muscle prevents tumor necrosis factor-alpha-induced insulin resistance</article-title><source>J Biol Chem</source><year>2007</year><volume>282</volume><fpage>7783</fpage><lpage>7789</lpage><pub-id pub-id-type="doi">10.1074/jbc.M608602200</pub-id></citation><citation citation-type="display-unstructured">Bouzakri K, Zierath JR (2007) MAP4K4 gene silencing in human skeletal muscle prevents tumor necrosis factor-alpha-induced insulin resistance. J Biol Chem 282:7783&#x02013;7789 <pub-id pub-id-type="pmid">17227768</pub-id></citation></ref><ref id="CR16"><label>16.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Al-Khalili</surname><given-names>L</given-names></name><name><surname>Chibalin</surname><given-names>AV</given-names></name><name><surname>Kannisto</surname><given-names>K</given-names></name><etal/></person-group><article-title>Insulin action in cultured human skeletal muscle cells during differentiation: assessment of cell surface GLUT4 and GLUT1 content</article-title><source>Cell Mol Life Sci</source><year>2003</year><volume>60</volume><fpage>991</fpage><lpage>998</lpage></citation><citation citation-type="display-unstructured">Al-Khalili L, Chibalin AV, Kannisto K et al (2003) Insulin action in cultured human skeletal muscle cells during differentiation: assessment of cell surface GLUT4 and GLUT1 content. Cell Mol Life Sci 60:991&#x02013;998 <pub-id pub-id-type="pmid">12827286</pub-id></citation></ref><ref id="CR17"><label>17.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Austin</surname><given-names>RL</given-names></name><name><surname>Rune</surname><given-names>A</given-names></name><name><surname>Bouzakri</surname><given-names>K</given-names></name><name><surname>Zierath</surname><given-names>JR</given-names></name><name><surname>Krook</surname><given-names>A</given-names></name></person-group><article-title>siRNA-mediated reduction of inhibitor of nuclear factor-kappaB kinase prevents tumor necrosis factor-alpha-induced insulin resistance in human skeletal muscle</article-title><source>Diabetes</source><year>2008</year><volume>57</volume><fpage>2066</fpage><lpage>2073</lpage><pub-id pub-id-type="doi">10.2337/db07-0763</pub-id></citation><citation citation-type="display-unstructured">Austin RL, Rune A, Bouzakri K, Zierath JR, Krook A (2008) siRNA-mediated reduction of inhibitor of nuclear factor-kappaB kinase prevents tumor necrosis factor-alpha-induced insulin resistance in human skeletal muscle. Diabetes 57:2066&#x02013;2073 <pub-id pub-id-type="pmid">18443205</pub-id></citation></ref><ref id="CR18"><label>18.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sabin</surname><given-names>MA</given-names></name><name><surname>Stewart</surname><given-names>CE</given-names></name><name><surname>Crowne</surname><given-names>EC</given-names></name><etal/></person-group><article-title>Fatty acid-induced defects in insulin signalling, in myotubes derived from children, are related to ceramide production from palmitate rather than the accumulation of intramyocellular lipid</article-title><source>J Cell Physiol</source><year>2007</year><volume>211</volume><fpage>244</fpage><lpage>252</lpage><pub-id pub-id-type="doi">10.1002/jcp.20922</pub-id></citation><citation citation-type="display-unstructured">Sabin MA, Stewart CE, Crowne EC et al (2007) Fatty acid-induced defects in insulin signalling, in myotubes derived from children, are related to ceramide production from palmitate rather than the accumulation of intramyocellular lipid. J Cell Physiol 211:244&#x02013;252 <pub-id pub-id-type="pmid">17219404</pub-id></citation></ref><ref id="CR19"><label>19.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ichinoseki-Sekine</surname><given-names>N</given-names></name><name><surname>Naito</surname><given-names>H</given-names></name><name><surname>Tsuchihara</surname><given-names>K</given-names></name><etal/></person-group><article-title>Provision of a voluntary exercise environment enhances running activity and prevents obesity in Snark-deficient mice</article-title><source>Am J Physiol Endocrinol Metab</source><year>2009</year><volume>296</volume><fpage>E1013</fpage><lpage>E1021</lpage><pub-id pub-id-type="doi">10.1152/ajpendo.90891.2008</pub-id></citation><citation citation-type="display-unstructured">Ichinoseki-Sekine N, Naito H, Tsuchihara K et al (2009) Provision of a voluntary exercise environment enhances running activity and prevents obesity in Snark-deficient mice. Am J Physiol Endocrinol Metab 296:E1013&#x02013;E1021 <pub-id pub-id-type="pmid">19276392</pub-id></citation></ref><ref id="CR20"><label>20.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sakamoto</surname><given-names>K</given-names></name><name><surname>McCarthy</surname><given-names>A</given-names></name><name><surname>Smith</surname><given-names>D</given-names></name><etal/></person-group><article-title>Deficiency of LKB1 in skeletal muscle prevents AMPK activation and glucose uptake during contraction</article-title><source>EMBO J</source><year>2005</year><volume>24</volume><fpage>1810</fpage><lpage>1820</lpage><pub-id pub-id-type="doi">10.1038/sj.emboj.7600667</pub-id></citation><citation citation-type="display-unstructured">Sakamoto K, McCarthy A, Smith D et al (2005) Deficiency of LKB1 in skeletal muscle prevents AMPK activation and glucose uptake during contraction. EMBO J 24:1810&#x02013;1820 <pub-id pub-id-type="pmid">15889149</pub-id></citation></ref><ref id="CR21"><label>21.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mu</surname><given-names>J</given-names></name><name><surname>Brozinick</surname><given-names>JT</given-names><suffix>Jr</suffix></name><name><surname>Valladares</surname><given-names>O</given-names></name><name><surname>Bucan</surname><given-names>M</given-names></name><name><surname>Birnbaum</surname><given-names>MJ</given-names></name></person-group><article-title>A role for AMP-activated protein kinase in contraction- and hypoxia-regulated glucose transport in skeletal muscle</article-title><source>Mol Cell</source><year>2001</year><volume>7</volume><fpage>1085</fpage><lpage>1094</lpage><pub-id pub-id-type="doi">10.1016/S1097-2765(01)00251-9</pub-id></citation><citation citation-type="display-unstructured">Mu J, Brozinick JT Jr, Valladares O, Bucan M, Birnbaum MJ (2001) A role for AMP-activated protein kinase in contraction- and hypoxia-regulated glucose transport in skeletal muscle. Mol Cell 7:1085&#x02013;1094 <pub-id pub-id-type="pmid">11389854</pub-id></citation></ref><ref id="CR22"><label>22.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jorgensen</surname><given-names>SB</given-names></name><name><surname>Viollet</surname><given-names>B</given-names></name><name><surname>Andreelli</surname><given-names>F</given-names></name><etal/></person-group><article-title>Knockout of the alpha2 but not alpha1 5&#x02032;-AMP-activated protein kinase isoform abolishes 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranosidebut not contraction-induced glucose uptake in skeletal muscle</article-title><source>J Biol Chem</source><year>2004</year><volume>279</volume><fpage>1070</fpage><lpage>1079</lpage><pub-id pub-id-type="doi">10.1074/jbc.M306205200</pub-id></citation><citation citation-type="display-unstructured">Jorgensen SB, Viollet B, Andreelli F et al (2004) Knockout of the alpha2 but not alpha1 5&#x02032;-AMP-activated protein kinase isoform abolishes 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranosidebut not contraction-induced glucose uptake in skeletal muscle. J Biol Chem 279:1070&#x02013;1079 <pub-id pub-id-type="pmid">14573616</pub-id></citation></ref><ref id="CR23"><label>23.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Al-Khalili</surname><given-names>L</given-names></name><name><surname>Bouzakri</surname><given-names>K</given-names></name><name><surname>Glund</surname><given-names>S</given-names></name><name><surname>Lonnqvist</surname><given-names>F</given-names></name><name><surname>Koistinen</surname><given-names>HA</given-names></name><name><surname>Krook</surname><given-names>A</given-names></name></person-group><article-title>Signaling specificity of interleukin-6 action on glucose and lipid metabolism in skeletal muscle</article-title><source>Mol Endocrinol</source><year>2006</year><volume>20</volume><fpage>3364</fpage><lpage>3375</lpage><pub-id pub-id-type="doi">10.1210/me.2005-0490</pub-id></citation><citation citation-type="display-unstructured">Al-Khalili L, Bouzakri K, Glund S, Lonnqvist F, Koistinen HA, Krook A (2006) Signaling specificity of interleukin-6 action on glucose and lipid metabolism in skeletal muscle. Mol Endocrinol 20:3364&#x02013;3375 <pub-id pub-id-type="pmid">16945991</pub-id></citation></ref><ref id="CR24"><label>24.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kern</surname><given-names>PA</given-names></name><name><surname>Ranganathan</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Wood</surname><given-names>L</given-names></name><name><surname>Ranganathan</surname><given-names>G</given-names></name></person-group><article-title>Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance</article-title><source>Am J Physiol Endocrinol Metab</source><year>2001</year><volume>280</volume><fpage>E745</fpage><lpage>E751</lpage></citation><citation citation-type="display-unstructured">Kern PA, Ranganathan S, Li C, Wood L, Ranganathan G (2001) Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab 280:E745&#x02013;E751 <pub-id pub-id-type="pmid">11287357</pub-id></citation></ref><ref id="CR25"><label>25.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Legembre</surname><given-names>P</given-names></name><name><surname>Schickel</surname><given-names>R</given-names></name><name><surname>Barnhart</surname><given-names>BC</given-names></name><name><surname>Peter</surname><given-names>ME</given-names></name></person-group><article-title>Identification of SNF1/AMP kinase-related kinase as an NF-kappaB-regulated anti-apoptotic kinase involved in CD95-induced motility and invasiveness</article-title><source>J Biol Chem</source><year>2004</year><volume>279</volume><fpage>46742</fpage><lpage>46747</lpage><pub-id pub-id-type="doi">10.1074/jbc.M404334200</pub-id></citation><citation citation-type="display-unstructured">Legembre P, Schickel R, Barnhart BC, Peter ME (2004) Identification of SNF1/AMP kinase-related kinase as an NF-kappaB-regulated anti-apoptotic kinase involved in CD95-induced motility and invasiveness. J Biol Chem 279:46742&#x02013;46747 <pub-id pub-id-type="pmid">15345718</pub-id></citation></ref></ref-list><glossary><title>Abbreviations</title><def-list><def-item><term>AICAR</term><def><p>5-Aminoimidazole-4-carboxamide-1&#x003b2;-4-ribofuranoside</p></def></def-item><def-item><term>AMPK</term><def><p>AMP-activated protein kinase</p></def></def-item><def-item><term>IR</term><def><p>Insulin resistance</p></def></def-item><def-item><term>siRNA</term><def><p>Small interfering RNA</p></def></def-item><def-item><term>SNARK</term><def><p>Sucrose, non-fermenting 1/AMP-activated protein kinase-related kinase</p></def></def-item></def-list></glossary></back></article> 